

13th ANRS HBV Cure Workshop Program
25th & 26th March 2026, at Institut Lumière, Lyon, France

Wednesday, 25th March 2026

Joint opening and closing statements for RNH / HBV Cure Workshop 10:30 – 10:45

Yazdan Yazdanpanah, Éloi Verrier & Fabien Zoulim

Young investigator session 10:45 – 12:15

Chairs: Jean-Michel Pawlotsky and Éloi Verrier

HBV cure and RNH joint session

Keynote lecture: 12:15 – 12:45

Chair: Raymond Schinazi

What are the knowledge gaps to cure HBV and HDV infections?

Massimo Levrero, Lyon

Lunch break (1:05')

Best Young Researcher Presentation Award 13:50

Viral genome persistence 14:00 – 14:50

Chairs: Christine Neuveut and Guillaume Giraud

Viral chromatin: the role of nucleosome occupancy in cccDNA transcription

Robert Schwartz, New York

Episomal and integrated hepatitis B transcriptome mapping in the liver of CHB patients

Jane McKeating, Oxford

Immunological determinants of viral persistence 14:50 – 15:40

Chairs: Pierre Tonnerre and Hélène Strick-Marchand

Beyond exhaustion: T cell adaptation in chronic HBV infection

Maike Hofmann, Freiburg

Distinct B cell phenotypes in chronic Hepatitis B precede spontaneous HBsAg clearance

Lucy Cooper, London

Break (20')

The liver reservoir of infection 16:00 – 17:15

Chairs: Andres Roca and David Durantel

Spatial single-cell omics: new insights into liver diseases.

Bertram Bengsch, Freiburg

Single-cell landscape of the myeloid cell adaptations during liver fibrosis

Moritz Peiseler, Berlin

Heterogeneity of HBV/HDV and immune response distribution in the liver

Maëlle Locatelli, Barcelona

End of day 17:30



13th ANRS HBV Cure Workshop Program
25th & 26th March 2026, at Institut Lumière, Lyon, France

Thursday 26th March, 2026

Novel therapies – Translational studies 8:30 – 10:10

Chairs: Patrick Soussan and Barbara Testoni

Induction of HBV-specific immune responses in immunocompetent humanized mice

Hélène Strick-Marchand, Paris

Development of novel therapeutic vaccine candidates

Anna Kosinska, Munich

Gene and epigenome editing of HBV

Anuj Kumar & Fabien Zoulim, Lyon

New approach to target HDV with antisense oligonucleotides

Julie Lucifora, Lyon

Break (15')

Cohort studies 10:25 – 11:40

Chairs: Vincent Thibault and Lucia Parlati

Hepatocellular carcinoma risk in a real-life cohort of chronic hepatitis B

Marc Bourlière, Marseille

Immune profiling of patients with CHB and CHD

Upkar Gill, London

Artificial intelligence in cohort studies and clinical trials for CHB and CHD

Anders Boyd, Bern

Novel therapies – Progress in clinical development 11:40 – 12:55

Chairs: Vincent Leroy and Hélène Fontaine

Treatment endpoints to guide clinical development of novel therapies

Jordan Feld, Toronto

Advances in RNA interference development

Man-Fung Yuen, Hong Kong

An update on Bulevirtide and novel treatments for CHD

Elisabetta Degasperri, Milan

Farewell and buffet lunch